source
- MapLight shifts focus to schizophrenia drug after mixed Phase 2 results, raises $150 millionMapLight Therapeutics reported mixed outcomes from its Phase 2 Zephyr trial of the muscarinic agonist ML-007C-MA. A twice‑daily dose achieved the study’s primary endpoint with notable reductions in…
- Industry groups urge FDA to add clarity and flexibility to manufacturer-payor communication guidanceIndustry associations and other stakeholders have asked the U.S. Food and Drug Administration to give more detail and flexibility in its updated guidance on how drug and device makers talk with pay…